Prenatal Genome-Wide Cell-Free DNA Screening: Three Years of Clinical Experience in a Hospital Prenatal Diagnostic Unit in Spain
Authors:
- Laia Pedrola VidalLVLaia Pedrola Vidal
- Mónica Roselló PieraMPMónica Roselló Piera
- Carla Martín-GrauCMCarla Martín-Grau
- Juan S. Rubio MollJMJuan S. Rubio Moll
- Rosa Gómez PorteroRPRosa Gómez Portero
- Beatriz Marcos PuigBPBeatriz Marcos Puig
- Jose V. Cervera ZamoraJZJose V. Cervera Zamora
- Ramiro QuirogaRQRamiro Quiroga
- Carmen Orellana AlonsoCACarmen Orellana Alonso
Open Access
Abstract
Genome-wide prenatal cell-free DNA (cfDNA) screening can be used to screen for a wide range of fetal chromosomal anomalies in pregnant patients. In this study, we describe our clinical experience with a genome-wide cfDNA assay in screening for common trisomies, sex chromosomal aneuploidies (SCAs), rare autosomal aneuploidies (RAAs), and copy-number variations (CNVs) in about 6000 patients over a three-year period at our hospital’s Prenatal Diagnostic Unit in Spain. Overall, 204 (3.3%) patients had a high-risk call, which included 76 trisomy 21, 21 trisomy 18, 7 trisomy 13, 29 SCAs, 31 RAAs, 31 CNVs, and 9 cases with multiple anomalies. The diagnostic outcomes were obtained for the high-risk cases when available, allowing for the calculation of positive predictive values (PPVs). Calculated PPVs were 95.9% for trisomy 21, 77.8% for trisomy 18, 66.7% for trisomy 13, 10.7% for RAAs, and 10.7% for CNVs. Pregnancy and birth outcomes were also collected for the majority of RAA and CNV cases. Adverse perinatal outcomes for some of these cases included preeclampsia, fetal growth restriction, preterm birth, reduced birth weight, and major congenital structural abnormalities. In conclusion, our study showed strong performance for genome-wide cfDNA screening in a large cohort of pregnancy patients in Spain.Keywords
Funding Information
- Illumina, Inc.
This publication has 29 references indexed in Scilit:
- Non-invasive prenatal testing can detect silent cancers in expecting mothersGenes & Diseases, 2024
- Position statement from the International Society for Prenatal Diagnosis on the use of non‐invasive prenatal testing for the detection of fetal chromosomal conditions in singleton pregnanciesPrenatal Diagnosis, 2023
- Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)Genetics in Medicine, 2022
- Cell‐free DNA screening for rare autosomal trisomies and segmental chromosome imbalancesPrenatal Diagnosis, 2022
- The predictive value of prenatal cell-free DNA testing for rare autosomal trisomies: a systematic review and meta-analysisAmerican Journal of Obstetrics and Gynecology, 2022
- Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 studyThe American Journal of Human Genetics, 2022
- TRIDENT-2: National Implementation of Genome-wide Non-invasive Prenatal Testing as a First-Tier Screening Test in the NetherlandsThe American Journal of Human Genetics, 2019
- Rare autosomal trisomies: Important and not so rarePrenatal Diagnosis, 2018
- RETIRED: No. 348-Joint SOGC-CCMG Guideline: Update on Prenatal Screening for Fetal Aneuploidy, Fetal Anomalies, and Adverse Pregnancy OutcomesJournal of Obstetrics and Gynaecology Canada, 2017
- Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in EuropeEuropean Journal of Human Genetics, 2012